A multicenter study found that deep learning analysis of single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) improved the diagnosis of obstructive coronary artery disease. The new method showed increased sensitivity and accuracy compared to traditional methods, leading to better patient outcomes.
A 12-year retrospective clinical study shows the long-term effectiveness of PRRT, allowing patients to maintain a high quality of life. The overall response rate is about 70-80 percent, and prognosis is generally favorable for patients who respond to therapy.
Researchers have discovered a new PET imaging biomarker that can better predict the progression of Alzheimer's disease. Microglial activation levels, as measured by TSPO-PET imaging, showed a significant correlation with cognitive outcomes in an amyloid mouse model.
The first total-body PET/CT scanner has shown promising results in enhancing image quality, reducing scan time, and lowering dose. Clinical trials have demonstrated improved diagnostic capabilities with minimal impact on patient exposure.
Researchers have identified two new nuclear medicine tracers that provide high-contrast images for cancer diagnosis, allowing for shorter imaging times and no diet changes. The tracers target cancer-associated fibroblasts, promoting tumor growth, migration, and progression.
PET/CT scans can monitor immunotherapy treatment for metastatic melanoma and predict outcome, allowing personalized therapy adjustments. The study demonstrates that FDG PET/CT can accurately assess tumor response to checkpoint inhibitor therapy with ipilimumab.
Researchers have developed a novel PET/CT tracer that detects and characterizes blood clots in the legs, where conventional imaging has limitations. The new imaging agent may provide more accurate diagnoses and information on clot growth or embolization, leading to changes in clinical intervention.
Researchers have found that a new PET imaging agent, 18F-FFNP, can measure changes in progesterone receptor levels resulting from hormone therapy for breast cancer patients. This could provide an earlier indicator of therapy effectiveness and inform individualized treatment decisions.
Researchers found that combining iodine-123 metaiodobenzylguanidine (123I-MIBG) SPECT imaging with cardiac magnetic resonance imaging (MRI) helps identify specific subsets of heart tissue more prone to arrhythmias. This approach enables physicians to achieve improved VT suppression and shorter procedure times.
A new PET probe targets melanin pigment in skin cancer lesions to improve detection of primary and metastatic melanoma. The probe shows promising results in clinical trials, outperforming existing methods like 18F-FDG PET/CT scans.
PSMA-targeted PET/MRI performs equally well as clinical nomograms to determine risk for advanced disease in high-risk prostate cancer patients, providing valuable information for treatment planning. The study results show whole-body imaging with 68Ga-PSMA-11 PET/MRI offers a one-stop shop for staging and guiding treatment options.
A new second-generation positron emission tomography (PET) tracer has been identified for imaging tau pathology in Alzheimer's disease patients. The tracer, 18F-RO-948, showed promising results in a human evaluation study, outperforming other novel tau-specific radiopharmaceuticals.
Researchers used PSMA PET/CT to detect prostate cancer outside the prostate gland with higher sensitivity and specificity than standard imaging techniques. This improved accuracy enables more precisely targeted treatment, potentially increasing the chances of successful outcomes.
Researchers developed a novel SPECT tracer to image c-Met expression in NSCLC, producing clearer images in less time and reducing radiation exposure. The tracer showed high specificity and rapid clearance from the body, making it potentially suitable for clinical use.
A new preclinical study shows that PET imaging with the 18F-FAC radiotracer can image T cells in the liver, potentially reducing biopsies and improving treatment. The approach could lead to personalized treatment of patients with immune-related liver disease.
A new PET imaging radiotracer, <sup> 18 </sup> F-XTRA, was tested on adults to study the distribution of the α4β2 nicotinic acetylcholine receptor in the brain. The research found that the radiotracer rapidly entered the brain and distributed quickly, with lower binding in the hippocampus with healthy aging.
A recent study highlights the potential for misinterpretation of Prostate-Specific Membrane Antigen (PSMA) PET results, which can affect diagnostic accuracy and guide therapy. Researchers urge nuclear medicine physicians to analyze PSMA-ligand uptake in conjunction with lesion localization to avoid misdiagnosis.
A new imaging method targets cancer-associated fibroblasts to diagnose widespread tumors like breast, colon, and pancreas cancer with better accuracy and less inconvenience. The tracer shows high tumor uptake and image contrast, making it a promising strategy for detection and treatment of malignant tumors.
Researchers used a PET tracer to identify differences in ER expression across metastases and surrounding normal tissue in breast cancer patients. The study found that approximately 50% of patients had one or more estrogen-receptor negative lesions, highlighting the heterogeneity of ER expression.
Researchers have developed a novel PET imaging method that can measure beta-cell mass, enhancing the ability to monitor and guide diabetes therapies. The new imaging method uses a radioligand to identify beta cells and has shown promising results in differentiating between healthy individuals and those with type 1 diabetes.
The Society of Nuclear Medicine and Molecular Imaging's Technologist Section recognized contributions from April Mann, Cybil Nielsen, Cheryl Rickley, and Lynne Roy for their dedication to advancing nuclear medicine technology. The awards highlight the impact of these individuals on education, advocacy, and service in the field.
The Journal of Nuclear Medicine's impact factor increased by 12% in 2017, ranking fifth among medical imaging journals. Citations to the journal rose from 24,977 to 27,101.
A new PET imaging method evaluates the extent of rheumatoid arthritis inflammation by targeting translocator protein (TSPO) expression in joint lining tissue. The study demonstrates that TSPO PET can image not only synovial macrophages but also activated synovial fibroblasts, a critical process in RA pathogenesis.
A novel, affibody-based pretargeted radionuclide therapy for HER2-expressing cancers demonstrated non-toxicity to the kidneys and improved survival in mice. The treatment delivered an absorbed dose to tumors that exceeded the dose to critical organs.
The Society of Nuclear Medicine and Molecular Imaging's 65th Annual Meeting showcased advancements in theranostics, quantitative nuclear imaging, and multimodality molecular imaging. Key findings include improved diagnostic accuracy and treatment options for various diseases, highlighting the potential for precision health.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced the selection of 14 new Fellows, recognizing their excellence in volunteer service, scientific discovery, and clinical practice. The SNMMI Fellowship is one of the most prestigious formal recognitions available to long-time members.
Researchers found improved quality of life and reduced tumor spread in patients treated with LuPSMA therapy. PSMA PET imaging demonstrated exceptional responses, correlating with significant reductions in PSA levels.
A study presented at the SNMMI Annual Meeting found that early treatment of advanced prostate cancer with lutetium-177 radioligand therapy can significantly prolong life, with a median overall survival of 27 months. Patients who received first-line therapy also had the longest survival rates.
A clinical trial found that 59% of patients with biochemical recurrence of prostate cancer had their clinical management changed by fluciclovine PET/CT imaging. The study detected disease in the prostate, pelvic lymph nodes, and less commonly, bone, guiding treatment decisions for men with recurrent prostate cancer.
A novel intelligent theranostic agent was designed to target tumors, with the ability to self-assemble in the tumor microenvironment and activate for therapy guided by photoacoustic imaging. The clusters showed high selectivity to the tumor microenvironment and eliminated tumor growth without subsequent recurrence.
Researchers have developed a novel approach to pretargeted radioimmunotherapy, which has shown complete responses in several solid tumor types using the beta-emitting lutetium-177 and alpha-emitting actinium-225. The new approach offers greater versatility of treatment for various solid tumors and clinical situations.
A new long-lasting type of radionuclide therapy has been proven effective in treating advanced neuroendocrine tumors, with the treatment lasting up to 4 times longer than previous options. The therapy, Lutathera-177 (Lu-DOTA-EB-TATE), was well-tolerated and showed promising results in a Phase I trial.
Gambhir's work on multimodality molecular imaging has advanced nuclear medicine and healthcare. He has developed strategies to study gene and cell therapies, and his lab has more than 625 publications and over 40 patents pending.
A new molecular imaging method allows early assessment of gene therapy success, potentially improving treatment for Parkinson's and Alzheimer's diseases. The PET reporter gene/probe system enables noninvasive monitoring of gene expression in all brain areas.
Researchers have developed a novel nuclear medicine probe that can detect synaptic density loss in the brain, a key biomarker for neurodegenerative diseases like Alzheimer's. The probe, using positron emission tomography (PET) imaging, has high imaging characteristics and is suitable for clinical trials and commercialization.
Richard L. Wahl, MD, has been recognized for his pioneering work in radioimmunotherapy, PET scans, and fusion imaging. His research has significantly contributed to understanding cancer prognosis, treatment response, and the importance of metabolic activity.
Simon Cherry has made significant contributions to biomedical imaging instrumentation and technology development, including microPET and hybrid PET/MRI systems. He is widely recognized for his work on molecular imaging and has received numerous awards for his achievements.
Researchers have demonstrated that combining targeted radionuclide therapy with immunotherapy can enhance treatment response and lead to a high cure rate in melanoma patients. This novel approach uses yttrium-86 (Y-86) NM600, which selectively targets tumors and delivers precise radiation doses.
A novel PET tracer has been developed to accurately image cardiovascular infections, which are extremely dangerous and have a high fatality rate. The tracer, called 6'-[18F]Fluoromaltotriose, is transported into bacterial cells by a membrane transport system exclusive to bacteria, allowing for specific imaging of bacterial infections.
Researchers developed a novel PSMA-targeting agent by conjugating MCG with an albumin-binding Evans blue derivative, improving tumor delivery and increasing the therapeutic effect. The agent showed significant tumor growth inhibition and complete eradication of tumors in mice, suggesting a promising strategy for cancer management.
Researchers have developed a new nuclear medicine procedure that can safely and effectively detect cancerous gastrointestinal and pancreatic neuroendocrine tumors. The novel radiolabeled tracer Ga-OPS202 has been shown to improve imaging contrast and sensitivity for detecting primary tumors or liver metastases.
A novel PET imaging method uses antibody fragment probes to target immune cells, detecting inflammation in the bowel and potentially guiding biopsies. The technique has wide applications in various diseases and could unlock assessment of inflammation.
Researchers developed a novel PET tracer that targets joint inflammation and can visualize active inflammation sites in arthritic joints. The tracer, fluorine-18 F-FEDAC, shows promise for early detection of rheumatoid arthritis, potentially improving treatment outcomes.
Researchers developed a DOTA-conjugated NTR1 antagonist to treat and monitor pancreatic cancer, showing significant tumor growth inhibition in early studies. The novel procedure was well-tolerated by patients, with one experiencing improved symptoms and quality of life.
A new PET tracer has shown potential in predicting treatment effectiveness for depression by measuring the level of serotonin transporter protein in the brain. The study found that patients who responded to treatment had lower levels of this protein before treatment began, suggesting a biomarker for remission.
Researchers have developed a new PET imaging agent that targets NMDA receptors in nerve cells to assess treatments for various neurological diseases. The agent, C-Me-NB1, provides valuable insights into the role of NMDA receptors in brain disorders.
A novel nuclear medicine imaging agent targeting copper accumulation in tumors detects prostate cancer recurrence early in patients with biochemical relapse. The new imaging agent, copper-64 chloride (64CuCl2), has a higher detection rate than fluorine-18-choline-PET/CT in patients with low levels of PSA (<1 ng/ml).
Researchers developed a new approach that uses a single PET scan to assess PD-L1 positive tumors, enabling personalized cancer treatment. The study demonstrates the feasibility of this non-invasive method, which may help guide treatment decisions and assess treatment response.
The Society of Nuclear Medicine and Molecular Imaging and the American Society of Nuclear Cardiology have issued joint guidelines for the clinical quantification of myocardial blood flow using Positron Emission Tomography (PET). The guidelines provide a comprehensive framework for the measurement and interpretation of myocardial blood ...
Researchers have developed a new method to differentiate cancerous tissue from healthy tissue in prostate cancer patients using PSMA PET/CT scans. The study found that a cutoff value of SUV max = 3.15 can accurately diagnose prostate cancer with high sensitivity and specificity.